IL13RA2 and glioblastoma: In a phase I study, recurrent glioblastoma and refractory glioblastoma were treated with CAR-T cells that have a high affinity to TAA interleukin-13 receptor α 2 (IL-13Rα2), which is overexpressed in recurrent glioblastoma.